FDA approved lenacapavir (Yeztugo) on August 18, 2025, solidifying the HIV portfolio for Gilead Sciences.
Steady: 1 in the last 7 days
Updated monday
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approved lenacapavir (Yeztugo) on August 18, 2025, solidifying the HIV portfolio for Gilead Sciences.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA grants tentative approval for lenacapavir.1 source
- Mercier joined Gilead Sciences as Chief Commercial Officer on August 14, 2025, while expert Tyler Van Buren commented on Yeztugo's early uptake trajectory.Sub-event
FDA approved lenacapavir (Yeztugo) for HIV prevention, solidifying Gilead's portfolio.1 source
FDA halted HIV clinical trials involving Gilead Sciences.1 source
Keep exploring
The entities involved
- FDA
-
Gilead Sciences
American company
Related events
Coverage
Newest first; wire copies grouped- thehindubusinessline.com
- insidermonkey.com
- ZacksGILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait? Shares of Gilead Sciences, Inc. (GILD) gained 7.3% after the company reported solid results for the second quarter of 2025 and raised it
- BarchartWhat to Expect From Gilead Sciences’ Q2 2025 Earnings Report Headquartered in Foster City, California, Gilead Sciences, Inc. (GILD) is a global biopharmaceutical leader committed to discovering, deve
- Insider MonkeyBernstein Maintains Buy Rating on Gilead Sciences (GILD) Stock Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of Bernstein maintain
- Unknown outlet
- Unknown outlet